[405] IMPLANTABLE PERITONEAL ULTRAFILTRATION DEVICE FOR FLUID OVERLOAD TREATMENT

Nitai Hanani, CEO, Paragate Medical, Israel

- **Investment Rational**
  Launched in 2016, Paragate Medical is addressing the white-space market opportunity of chronic fluid management in heart and kidney failure. Paragate aims to revolutionize patients' management by introducing the first ever chronic, fully implantable, home-based solution, to reduce healthcare burden. With strong leadership skillset, worldwide leading SAB and striking acknowledgement, the company looking towards initiating its first-in-human studies.

- **Business Strategy**
  Paragate's heart failure application shall have two revenue streams, through direct sales of the implantable system as well as remote monitoring and management platform, harnessing the patient's data to the HF unit, allowing economic savings of $100,000 per patient. Future renal application shall be distributed through dialysis-service providers, aspiring for integrated care while shortening sessions time and increasing dialysis throughput.

- **Core Technology** (and value proposition)
  Paragate is developing the first ever fully implantable, mechanical bypass of the kidneys, to actively and continuously (24/7) treat fluid overload to keep the "hospitals' frequent flyers" balanced at home with a will to live.
  The dialysis-free implantable peritoneal ultrafiltration device may offer a huge benefit to healthcare system, bearing the costs of repeated readmissions, dialyses and patient management burden.

- **Product Profile/Pipeline**
  With global target population of 4.5 million advanced heart failure and chronically congested patients and with 500,000 annual incidents, the potential annual market exceeds $15B. The company has secured clinical collaborations and validated potential interest throughout major healthcare disciplines and potential distributors and acquirers. Future pipeline renal product is designated to solve inter-dialytic weight-gain complications to improve dialysis care efficiency.

- **What's Next?**
  Paragate it seeking to complete a syndicate-based series A to conduct first-in-human trials with its established sites, regulatory pre-submissions under breakthrough designation and expand its operations.